ARCHIVES

As patients worry about COX-2 inhibitors, scientists and FDA review toxicity data.

This article is from The Cancer Letter archive.

Vol. 30 No. 40 | October 22, 2004

Download PDF Visit The Full Archive

Related Articles

Drugs and Targets: Cyramza approved in metastatic stomach cancer

November 7, 2014

In Brief: Hammer Appointed To New Three Year Term, Says As Panel Chairman; ACCC Elects Yarbro, Moorhead

March 16, 1984

Drug Reimbursement: Senate Bill Worse For Oncologists

July 11, 1997

ACS Expresses Concern About “Fletcher Report” On Mammography

May 7, 1993

Translation Of “New Biology” Into Clinical Use Identified By DeVita As NCI’s Major Challenge

August 16, 1985

Radiation Oncology To Become Crowded, ACR Warns Physicians

December 15, 1995